Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The HVAD™ Pump is the world’s smallest commercially available, full-support, centrifugal VAD, enabling unmatched procedural versatility. It is also the only full-support, durable VAD with clinical evidence to prove its safety and effectiveness when used in a less-invasive thoracotomy approach.
The latest clinical evidence from the HVAD LATERAL Trial demonstrated a significant improvement in quality of life, including 87% unprecedented survival at 2 years and 30% reduced length of stay.1
Unprecedented Survival at 2 Years1
Reduced Length of Stay1
FREEDOM FROM DISABLING STROKE2 as demonstrated from the latest clinical evidence from the HVAD LATERAL trial
EXCHANGE
Exchange for VAD thrombus was only 2.1% with no new events between 1–2 years2
Data submitted for publication.
0.12 EPPY
Driveline infection rate2
Data submitted for publication.
0.10 EPPY
Stroke rate2
Data submitted for publication.
Low Incidence of Right Heart Failure2:
Data submitted for publication.
A number of centers are beginning to study the potential impact that implanting the HVAD Pump via a less-invasive thoracotomy approach may have on the incidence of right heart failure.3
"We retrospectively reviewed our cohort of HVAD implantations between 2013 and 2017, and found that the lateral group was associated with less RV dysfunction compared with patients in the conventional sternotomy group."3
Zachary N. Kon, M.D.
New York University, New York, NY, USA
A recent study demonstrated that HVAD implant using the less-invasive thoracotomy approach has a $56,385 reduction in costs compared to HVAD implant using the sternotomy approach.4
READ ABSTRACTEconomic LATERAL Data (N = 95) | Medicare Data (N = 2,831) |
---|---|
HVAD Thoracotomy Population Only | Predominantly VAD Sternotomy Population |
Both focused exclusively on cost of VAD implant hospitalization |
Relative reduction in LOS compared to sternotomy approach1
Absolute average reduction in cost compared to sternotomy approach4
The percentage of HVADs implanted via the less-invasive thoracotomy approach has continued to rise as the clinical evidence and positive patient outcomes continue to build. Today, an average of 26% of HVAD Pumps are implanted via a thoracotomy approach.5
Average percent of HVAD Pumps that are implanted via a thoracotomy approach5
Ask your Medtronic sales rep about optimized surgical tools designed specifically for use in thoracotomy procedures.
DOWNLOAD INFORMATIONInterested in learning more about the HVAD System and the less-invasive thoracotomy approach? Medtronic offers educational programs designed for clinicians interested in expanding their knowledge of VAD therapy and the HVAD System. To learn more about these educational opportunities, please speak with your Medtronic sales representative or register to access Medtronic Academy.
SEE EDUCATION OFFERINGSMcGee E Jr, Danter M, Strueber M, et al. Evaluation of a lateral thoracotomy implant approach for a centrifugal-flow left ventricular assist device: The LATERAL clinical trial. J Heart Lung Transplant. April 2019;38(4):344-351.
Wieselthaler G, et al. Temporal Adverse Event Profile following LVAD Implantation via a Thoracotomy Approach: 2 Year Follow-up of the LATERAL Trial. Presented at ASAIO 2019; San Francisco, CA.
Pasrija C, Sawan MA, Sorensen E, et al. Less invasive left ventricular assist device implantation may reduce right ventricular failure. Interact Cardiovasc Thorac Surg. October 1, 2019;29(4):592-598.
Mokadam NA, McGee E, Wieselthaler G, et al. Cost of Thoracotomy Approach: An Analysis of the LATERAL Trial. Ann Thorac Surg. Published online March 26, 2020.
U.S. source data on file with Medtronic as of October 2019.